Park Avenue Securities LLC bought a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 14,108 shares of the company's stock, valued at approximately $276,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Deep Track Capital LP bought a new position in shares of Genmab A/S in the fourth quarter valued at approximately $41,740,000. Renaissance Technologies LLC boosted its holdings in shares of Genmab A/S by 7.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock worth $40,199,000 after buying an additional 139,722 shares during the period. Two Sigma Investments LP grew its stake in Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock valued at $35,612,000 after buying an additional 938,455 shares during the last quarter. Two Sigma Advisers LP raised its holdings in Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after acquiring an additional 1,038,400 shares during the period. Finally, First Trust Advisors LP raised its holdings in Genmab A/S by 18.0% in the 4th quarter. First Trust Advisors LP now owns 1,644,288 shares of the company's stock worth $34,316,000 after acquiring an additional 251,241 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the stock. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Wall Street Zen lowered Genmab A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Finally, Truist Financial lowered their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $39.17.
Read Our Latest Research Report on GMAB
Genmab A/S Trading Down 2.1%
Shares of Genmab A/S stock traded down $0.47 during trading on Thursday, reaching $21.56. The company's stock had a trading volume of 1,846,492 shares, compared to its average volume of 1,176,521. The stock has a 50-day moving average price of $20.77 and a two-hundred day moving average price of $20.76. The stock has a market capitalization of $13.82 billion, a P/E ratio of 12.25, a price-to-earnings-growth ratio of 7.26 and a beta of 0.96. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $28.56.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The firm had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. As a group, sell-side analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.
Genmab A/S Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
